Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very true and I agree. I was commenting on very short term and interday short attacks on good news as racketeering in the stock market.
SAGE kept all US rights and 100% of the profits for US Japan and S Korea and got $1.5 million up front and another $1.5 billion plus in milestones. How on earth is that anything but a monster good deal for a 4 billion market cap company? $884 million immediately. Needless to say I did not have stop losses on SAGE and not selling.
By the way Dr Andrew Cole MD the preeminent authority in Epilepsy is on the Scientific Advisory Board of both SAGE and Anavex and no other Company.
Eight days of trend is down transversing a fairly steep upwards channel of 3 months and much more. Six weeks are accepted time frames for trends eight day are not. The pop over the trend channel to 2.5 for eight days was not a trend in either direction either rather it was an anomaly the quickly reverted to the upwards trend channel. The top of the channel is now $1.90 and rising. When it popped above the channel on Oct 15th the top of the channel was $1.33. Do the math.
Good RSI read. Good time to buy is when daily RSI is below 50% while weekly or monthly is 70% or greater. Same as buying in the lower ranges of an upwards sloping channel. It may not seem like it to some people looking emotionally and not mathematically but NWBO is in a fairly steep upward trend of approx $0.072 per day on average. Regression back up to the middle of the channel would be $1.62 and rising $.07 per day. Many times when stocks fall just below the channel they will revert to the mean fairly rapidly as NWBO did following a dip on Nov 10.
The 10 day average volume is 2.5 million shares for a full day. 1 million half way through is average not very small. Ignorant post. You are put on ignore.
Volume today in NWBO at over a million already about average. On what should have been a low volume day the volume is very good. With a 885 million Market Cap Trading Algos are tuned in. I beg to differ and believe the 50d ma is very significant and after the last time NWBO tested the 50d ma average on Nov 10 it rallied 40 cents which was about a 40% gain over the next two days. Lets see what happens this time but a rally to $1.44 seems very possible in the very short term.
There you have it. Successful test of $1.19 which has held for now. I bought a freighterfull at $1.20. I could not get $1.19 because even bigger boats were crowding the $1.19 dock. We could have clear sailing based on previous tests on the 50d ma. Next stop the barrier reef at $1.44. If NWBO can clear that it is open ocean to Galapagos Islands type valuation. They types of tumors DVAX might eventually treat are varied as wildlife on Galapagos Islands.
I would like to think the Government Agencies are out for the Citizens but after seeing the rampant Iraqi and Afgan War Profiteering by Chaney and Halliburton in those Wars I am no longer so naive. This Covid War if any good will come of it at all will be to expose corruption of Govt. Bureaucrats and advancement of science of controlling pandemics. Before we can solve the pandemic we need to control the corruption.
Maybe the Covid War Profiteering BP pigs have had their feast at the Government feeding troughs and they will let some of the little companies feed on some scraps so they can work on a truly effective drug.
Now that all the Big Pigs have gotten their EUAs and the vaccines are ready to roll they will start handing out EUAs on a more equitable and merit based system. It does seem like EUAs are accelerating.
I wonder how much of that decision rested on vaccines and other promising therapeutics as they said and how much because they see the FDA and Governments funding favoring BP Corona War Profiteers and stone walling small companies like Cytodyn and Equillium.
Share price is partly HFT deception especially the recent drop to $1.64 the rest is that the whole Covid therapuedic sector is down given over to recovery plays like once and current Dow leader Boeing. There will only be a few winners in Covid stocks going forward and they will suck all the oxygen in the space. I believe CYDY is one HGEN may be another as it could be combined with Remdesivir so the CCCP gains their Covid War Profiteering Goals.
CCCP = Central Commitee Covid Profiteers of the USA
Which has the same goals and methods as the Chinese and Russian CCCPs Communist Central Commitees which is to concentrate wealth and power for the goal of ever greater control of Goverments and Tyranny over citizens by Goverment bureaucracies for the purposes of even more wealth power and control. All of these CCCPs seem to be working together in a war against the citizens of the World. There is not a lot of difference between the mega billionaires of the US Russia and China they all own the Governments and they all are out to grasp even more wealth and power. The Covid War is just another battle in an escalating war against Democracy.
This is true as you say the chart looks for CYDY. But many of the Covid Therapeutics stocks charts look very similar to CYDY. Out of favor the last few months as there has been a rotation out of these and into Economic Recovery Stocks. Now it will come down to picking the individual winners instead of the therapeutics sector. I believe CytoDyn will be a winner not only in Covid but HIV and Cancer beyond Covid. So even if not Covid then still have a winner in other indications. CYDY is one of the few Covid Plays with even better primary long term value drivers beyond Covid.
Yes interesting that DMSB wants to look again not wait until all completed and not saying add more patients and complete. Very likely the safety and more importantly the efficacy was close to an approvable stat sig at 50% and feel the total N will not be necessary for approval. In other words " this is working shorten the trial and lets get this approved ASAP."
EQ is still just 1.5 x book value. Seems very low one would think it should be 3 or 4 x for graft vs host alone. Some attention on the Covid indication could cause another big spike in this low float stock like last summer when itolzimab got the India EUA.
Looks like the investor conferences convinced a few buyers as the stock price started to move up yesterday and today right after those conferences. Do you know if replays are available on EQ website. I have started a long position here after the recent pop and drop Clay did his video on. Seems like interest is building. Even without Covid the Graft v Host could be a very big deal.
If CYTODYN does not get both EUA and OWS funding at the next interim look then there is something Definately Wrong in the FDA and US Army. I do not place a lot of faith in FDA. OWS has prioritized vaccines now that that is on track one would assume that the Armed Forces establishment would start on therapeutics. There is risk in that a decision might be made to slow roll treatments to urge acceptance of vaccines or that OWS would listen to FDA about what is effective. There is a natural bias toward BP as they have wherewithal to complete the project. This is where a BP partnership would be crucial. AstraZeneca?
No not at all.
Shorts are likely lining up shares to borrow now so they can sell the spike that might come with top line data. But when it takes a margin balance of funds equal to $2.50 per share why not buy the stock and then just sell the spike? So maybe these prospective shorts are larger players that have accounts with a balance in excess of $25 million and therefore immune to the margin rules and limitations. Unless they only intend to short above $2.50
Maybe is was edited out as a BS answer to a direct question and possibly misleading. I did not take it as positive at all but an evasive answer to a direct question. Nader said " Just wait to see if we have $30 million at the end of December" in response to the question regarding shareholder dismay that the latest financing requires $7.5 million payback a month starting this month.( Which was so egregious that I thought it must be a typo- but now confirmed as true) I was indeed dismayed by that and even much more so after Nader BS answer in the proactive video.
WOW is right wow how F'ed up could it be.
Possibly but that is what some people thought would happen on PDD results. I thought that PDD would be a sell the news event as is nearly always the case with Anavex since July 2015. But you may be right with the Adult RETT news as Anavex has a good clean shot at RETT.
Very good and I agree. My cautionary comment was in regards to Avavex obtaining the voucher. For Avavex to receive the voucher they must gain approval for the orphan indication.
We can wish but that is not reality. The current RETT trial is adult. So maybe not approval for the children until they complete a pediatric trial. However if they prove the efficacy in Adult maybe a safety trial in children that would be quick with possible provisional use until full approval. However the market may price in eventual approval into AVXL stock price on strong results in Adult RETT. After all they have less than nothing now.
Too early to say the SAVA prospectus is toxic. It has neither been priced or sized. If it had no accompanying warrants then it will be just a normal type secondary. Priced well and well subscribed it might be anything but toxic. I do prefer urge Anavex trickle financing but each has its positives and negatives. The SAVA. secondary is the conventional type that attracts institutions and gets matter resolved until the next round. One can time accumulations by buying after these secondaries on the over reaction to the down side. Anavex does not have dips caused by these but there is capping pressure from the LPC periodic small sales. I am not a Cassava investor but it is an interesting concept and likely better approach than most BPs had been taking. Also the post market reaction means less than nothing in a sense may be deceptive.
There are both similarities and differences in the Anavex and SAVA MOAs, these two drugs may actually be complimentary. They both work on inflammation rather than the products of inflammation as Aducanumab proposed to do. I do not believe the SAVA drug is DOA and the Phase 3 may be an important advance to the science in this area.
It is becoming painfully clear however that Aducanumab will be DOA just as the other plaque reduction targeted drugs have been.
Dr Been has a video on Itolizimab. The US sponsors has clinical trials with it for Graft vs Host and planning US Clinical trial. Equillium...the stock jumped 50 % as much as 75% mid day today on no real news just analyst upgrade and the rebound in Covid19 Therapeutics Stocks. Itolizimab is generally well tolerated and has been approved for several years in India for another indication.
I would say Zika and West Nile Virus.
Then in future one could add Herpes Shingles, Lupus and RA. Any autoimmune disorders should be tried.
Steam who needs steam? EQ up 50% today only on analyst upgrade and the Covid19 Therapeutics rebound. F B Riley might do an offering for EQ now while CYDY did in non filutive fashion by convertible bond at $10 per share. $10 per share has crossed the ticker tape a few months ago. It might race pat that to $20. Good deal for the bond holder and CYDY.
One day soon we might get a day like EQ is getting today up 50% was up 75% mid day
Well if it was a planned sale then he knew when to release the results. Seemed like he would have had a reasonablely wide window to time that.
There is a bounce back in Covid19 Therapeutics today lead by CYDY SRNE and EQ. RLFTF as well. The market has tasted the Lilly bagel and decided it did not taste to good. It is missing the scmear..safety and convenience. Infusion in clinical setting with side effects for moderate stage as in Lilly Bmab is definately missing something. What until Mr Market tastes the CytoDyn bagel double smeared , safety and convenience of Doctors office, with lox..the other indications.
I hope you are both sending the Dr Patterson paper as well. Much appreciation to you both as always.
Except for FDA Politics. That is part of the landscape of any biotech. Politics = who gets what where and when and for how much.
This is true the US Government is paying for all the Vaccines and will be free to the end user. Same with Remdesivir that likely does very little but the Government is not paying much of a margin basically break even. Backstopping the efforts of BP so they can recoup their costs but not a lot more. Value to BP is brand enhancement and reputation which is very valuable good will asset that they can add to the balance sheet. Intangibles are hard to quantify but they have a lot of value. They can use intangibles like good will as part of the collateral to issue corporate bonds to buy a tangible asset like a company or a drug.
I believe you are referring to Humanagen.
This actually shows the opposite of what you say in that it tends the show the influence of Gilead to help its partner ( through the cancer deal with Kite a Gilead subsidiary) get some of this Government largess and consideration.
Yes I was not referring to retail but rather serious investors who may accumulate over time helping put a support floor on the share price. I think we have seen the capitulation today which may lead to a reversal short term and intermediate trend on no more news whatsoever except maybe a PR on the peer reviewed Dr Patterson paper.
I am with you on this sound logic of the long thesis for CYDY. Once today's peer reviewed Dr Patterson Leronlimab paper is digested by the big investors and BPs CYDY may see a major bounce from here.
The last two days seemed like capitulation from the Vaccine and Lilly news. With today's volume that should have worked itself out and CYDY may see a major reversal of the recent price trend. The Patterson paper could not have come at a better time. Bad news (seemingly bad but really almost irrelevant) out of the way now for the good news.
Down gaps at 2.12 and 2.55 might get filled easier now with the peer reviewed Dr Patterson LL paper might come serious long investors and BPs. CYDY is ecceedingly attractive to go long or cover short positions at today's prices.
Or at least a dragon fly doji reversal signal.
Excellent. Anyone that sold in the recent capitulation might have severe regrets when BPs come knocking on CYDY door.
This also nullifies the ambulance chasers claim LL was not suitable to deploy against Covid so no lawsuits will come from those attorney advertisements.
All BPs have failed so far in Severe to Critical so far. Halted the phase 3s at Interim. We got the green light and the unusual measure if another interim at 75% bodes very well. FDA may have been throwing a bone at Lilly to let them recover their development costs so the could redeploy on another battle in this Covid War. Any of these BPs with a set up supply chain on their current EUAs might look favorably on CYDY to partner on the Covid indication utilizing the resources they already deployed to set up the supply chains once the CYDY Phase 3 shows effectiveness.
Daily chart and volume looks like capitulation of long traders. The recent bounce off the bottom today is encouraging. 8 million shares in first hour and 48 minutes or 3x avg day looks like capitulation. I would not be surprised by a significant bounce the rest of the week. I do not expect a lot of selling going forward this week. We might end where we started the week even on no news. In fact the best thing for the company to do is STFU.